CalciMedica Inc. (CALC)
NASDAQ: CALCHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CALC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.69M
- EPS (TTM)
- -$4.41
- Dividend yield
- None
- 52-week range
- 1.00 – 36.00
- Day range
- 1.20 – 1.33
- Volume / Avg
- 86.25K / 80.15K
- Beta
- —
- Shares outstanding
- 6.90M
52-week range
CALC stock today
CalciMedica (CALC) closed at $1.26 on Nov 20, up 7.69% (+$0.09), versus the S&P 500's 3.70% decline. Shares are 96.5% below their 52-week high of $36.00, set on Dec 26, 2025 and 26.0% above the 52-week low of $1.00, near the bottom of the past year's range. CALC is down 96.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 92.3%.
CalciMedica has posted a net loss over the last twelve months (EPS of -$4.41), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CalciMedica
Company profileCalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. A. Rachel Leheny Ph.D.
- Headquarters
- La Jolla, CA
- Employees
- 15
- IPO year
- 2023
- Website
- calcimedica.com
Financial highlights
Full financialsCalciMedica reported a net loss of $29.6 million, compared with a loss of $13.7 million a year earlier. Diluted earnings per share came in at -$1.97.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-29.56M | $-13.70M | $-34.36M | $-7.82M | $-35.82M |
| EPS (diluted) | $-1.97 | $-1.22 | $-7.66 | $-111.16 | $-1.69 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$50.00+3868.25%
- Strong buy 0
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.24 vs $-0.75
- Surprise
- +68.00%
CALC news
All CALC newsCalciMedica peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OPTHOptimi Health Corp. | 1.51 | -13.71% | $8.65M | vs CALC |
| BIVIBioVie Inc. Class A | 0.80 | -12.07% | $8.58M | vs CALC |
| LEXXLexaria Bioscience Corp. | 4.03 | -10.24% | $8.49M | vs CALC |
| HINDVyome Holdings Inc. | 1.20 | -17.24% | $8.42M | vs CALC |
| GDTCCytoMed Therapeutics Limited | 0.755 | -2.33% | $9.01M | vs CALC |
| QNTMQuantum Biopharma Ltd. Class B Subordinate Voting Shares | 1.29 | -9.15% | $8.29M | vs CALC |
| MBRXMoleculin Biotech Inc. | 7.74 | -2.40% | $8.22M | vs CALC |
| PTNPalatin Technologies Inc. | 4.58 | -7.10% | $8.16M | vs CALC |
Indexes, lists and sector
CalciMedica stock FAQ
What is CalciMedica's stock price today?
CALC last traded at $1.26 as of Nov 20, 4:00 PM EST, up 7.69% on the day. Prices are delayed at least 15 minutes.
Does CalciMedica pay a dividend?
No. CalciMedica does not currently pay a regular cash dividend.
Who is CalciMedica's CEO?
Dr. A. Rachel Leheny Ph.D. is the chief executive officer of CalciMedica Inc., which has about 15 employees.
Has CALC ever split its stock?
Yes. The most recent CALC stock split was a 1-for-5 split on Aug 31, 2026.
What is the CALC 52-week high?
The 52-week high for CALC is $36.00 and the 52-week low is $1.00. The stock is currently 96.5% below its high.